Eric Roeland, MD: Toward Better Treatment for Cachexia
2015 Palliative Care in Oncology Symposium
Given the challenges of recruiting patients for palliative care studies, Eric Roeland, MD, of the University of California, San Diego, discusses a way to increase the participation of those with cachexia, with the hope of improving treatment (Abstract 67).
Betty Ferrell, PhD, RN
Betty Ferrell, PhD, RN, of City of Hope, discusses two papers that look at an important issue from different perspectives: depression and anxiety among family caregivers of patients with advanced cancer, and the link between oncologists’ dispositional affect and depressive symptoms in their patients with metastatic cancer (Abstracts 224, 214).
Diane Portman, MD
Diane Portman, MD, of Moffitt Cancer Center, discusses clinical pathways that embed palliative care along the spectrum of care for a variety of cancer disease states.
Charles L. Loprinzi, MD
Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Jennifer S. Temel, MD
As Steering Committee Chair of this year’s symposium, Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses the goals and highlights of the meeting.
Lawrence H. Einhorn, MD
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).